Target Price | $599.90 |
Price | $463.98 |
Potential | 29.29% |
Number of Estimates | 19 |
19 Analysts have issued a price target Synopsys 2026 . The average Synopsys target price is $599.90. This is 29.29% higher than the current stock price. The highest price target is $685.00 47.64% , the lowest is $520.00 12.07% . | |
A rating was issued by 24 analysts: 21 Analysts recommend Synopsys to buy, 3 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Synopsys stock has an average upside potential 2026 of 29.29% . Most analysts recommend the Synopsys stock at Purchase. |
18 Analysts have issued a sales forecast Synopsys 2025 . The average Synopsys sales estimate is $6.8b . This is 11.60% higher than the revenue of the last 12 months(TTM). The highest sales forecast is $6.8b 11.88% , the lowest is $6.7b 11.09% .
This results in the following potential growth metrics:
2024 | $6.1b | 15.22% |
---|---|---|
2025 | $6.8b | 10.59% |
2026 | $7.6b | 12.36% |
2027 | $8.6b | 13.32% |
2028 | $9.8b | 13.20% |
10 Analysts have issued an Synopsys EBITDA forecast 2025. The average Synopsys EBITDA estimate is $2.9b . This is 126.16% higher than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is $2.9b 130.49% , the lowest is $2.8b 121.13% .
This results in the following potential growth metrics and future EBITDA Margins:
2024 | $1.4b | 2.72% |
---|---|---|
2025 | $2.9b | 109.62% |
2026 | $3.3b | 16.14% |
2027 | $3.9b | 16.05% |
2028 | $4.4b | 14.74% |
2024 | 22.39% | 10.85% |
---|---|---|
2025 | 42.44% | 89.55% |
2026 | 43.87% | 3.37% |
2027 | 44.93% | 2.42% |
2028 | 45.54% | 1.36% |
10 Synopsys Analysts have issued a net profit forecast 2025. The average Synopsys net profit estimate is $1.6b . This is 24.79% lower than the net profit for the last 12 months(TTM). The highest net profit forecast is $1.7b 19.57% , the lowest is $1.6b 26.06% .
This results in the following potential growth metrics and future Net Margins:
2024 | $2.3b | 84.03% |
---|---|---|
2025 | $1.6b | 29.89% |
2026 | $1.8b | 15.20% |
2027 | $2.4b | 30.22% |
2028 | $2.8b | 16.65% |
2024 | 36.94% | 59.72% |
---|---|---|
2025 | 23.42% | 36.60% |
2026 | 24.01% | 2.52% |
2027 | 27.59% | 14.91% |
2028 | 28.44% | 3.08% |
10 Analysts have issued a Synopsys forecast for earnings per share. The average Synopsys EPS is $10.26 . This is 24.00% lower than earnings per share in the financial year 2024. The highest EPS forecast is $10.98 18.67% , the lowest is $10.09 25.26% .
This results in the following potential growth metrics and future valuations:
2024 | $14.51 | 83.21% |
---|---|---|
2025 | $10.26 | 29.29% |
2026 | $11.82 | 15.20% |
2027 | $15.40 | 30.29% |
2028 | $17.96 | 16.62% |
Current | 34.37 | 46.46% |
---|---|---|
2025 | 45.21 | 31.54% |
2026 | 39.24 | 13.21% |
2027 | 30.14 | 23.19% |
2028 | 25.83 | 14.30% |
Based on analysts' sales estimates for 2025, the Synopsys stock is valued at an EV/Sales of 10.06 and an P/S ratio of 10.62 .
This results in the following potential growth metrics and future valuations:
Current | 11.23 | 23.08% |
---|---|---|
2025 | 10.06 | 10.38% |
2026 | 8.96 | 11.00% |
2027 | 7.90 | 11.75% |
2028 | 6.98 | 11.66% |
Current | 11.86 | 20.27% |
---|---|---|
2025 | 10.62 | 10.39% |
2026 | 9.46 | 11.00% |
2027 | 8.34 | 11.75% |
2028 | 7.37 | 11.66% |
Analyst | Rating | Action | Date |
---|---|---|---|
Rosenblatt |
Buy
➜
Buy
|
Unchanged | May 29 2025 |
Piper Sandler |
Overweight
➜
Overweight
|
Unchanged | May 29 2025 |
Needham |
Buy
➜
Buy
|
Unchanged | May 29 2025 |
Keybanc |
Overweight
➜
Overweight
|
Unchanged | May 20 2025 |
B of A Securities |
Buy
➜
Buy
|
Unchanged | Apr 16 2025 |
Mizuho |
Outperform
➜
Outperform
|
Unchanged | Apr 15 2025 |
Keybanc |
Overweight
➜
Overweight
|
Unchanged | Apr 15 2025 |
Analyst Rating | Date |
---|---|
Unchanged
Rosenblatt:
Buy
➜
Buy
|
May 29 2025 |
Unchanged
Piper Sandler:
Overweight
➜
Overweight
|
May 29 2025 |
Unchanged
Needham:
Buy
➜
Buy
|
May 29 2025 |
Unchanged
Keybanc:
Overweight
➜
Overweight
|
May 20 2025 |
Unchanged
B of A Securities:
Buy
➜
Buy
|
Apr 16 2025 |
Unchanged
Mizuho:
Outperform
➜
Outperform
|
Apr 15 2025 |
Unchanged
Keybanc:
Overweight
➜
Overweight
|
Apr 15 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.